<DOC>
	<DOCNO>NCT00417248</DOCNO>
	<brief_summary>Sorafenib demonstrate vivo anti-tumor efficacy . This trial evaluate safety preliminary efficacy sorafenib follow chemoradiation locally advance NSCLC .</brief_summary>
	<brief_title>Cisplatin/Etoposide/Radiotherapy Followed Consolidation Sorafenib Inoperable Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Outline : This multi-center study . Chemotherapy/radiation therapy ( 2 cycle ) - Cisplatin 50 mg/m2 IV day 1 8 28 day cycle - Etoposide 50 mg/m2 IV day 1-5 28 day cycle - Concurrent chest radiation ( plan dose 5940 cGy additional , optional boost 1080 cGy total allow dose 7020 cGy ) following : Maintenance therapy Sorafenib 400 mg PO BID 28 day cycle , begin minimum 6 maximum 9 week completion chemo-radiotherapy PD , intolerable toxicity , 1 year . Patients progressive disease discontinue treatment . ECOG performance status 0 1 Hematopoietic : - Absolute neutrophil count ( ANC ) ≥ 1500 mm3 - Platelet count ≥ 100,000 mm3 - Hemoglobin ≥ 9 g/dL - PT INR &lt; 1.5 x ULN unless anti-coagulant therapy - PTT &lt; 1.5 x ULN unless anti-coagulant therapy Hepatic : - Bilirubin ≤ 1.5 x ULN - ALT ≤ 2.5 x ULN ( ≤ 5 x ULN patient liver involvement ) - AST ≤ 2.5 x ULN ( ≤ 5 x ULN patient liver involvement ) Renal : - Creatinine &lt; 1.5 X upper limit normal ( ULN ) Cardiovascular : - No significant history cardiac disease : Congestive heart failure &gt; class II NYHA . - Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within 90 day prior registration initial therapy ) myocardial infarction within 6 month prior registration initial therapy . Respiratory : - FEV1 ≥ 1 liter spirometry within 60 day prior registration initial therapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histological cytological proof nonsmall cell lung cancer ( NSCLC ) . Measurable nonmeasurable disease per RECIST . Unresectable Stage IIIA IIIB disease evaluate imaging . Must age ≥ 18 year time consent . Written inform consent HIPAA authorization release personal health information . Females childbearing potential male must willing use effective method contraception . Females childbearing potential must negative pregnancy test within 7 day prior register initial therapy . No prior chemotherapy radiotherapy lung cancer . No positive supraclavicular scalene lymph node extend cervical region . No superior sulcus ( pancoast tumor ) . No malignant pleural effusion . The exception patient pleural effusion visible CT scan ( visible CXR ) OR deem small tap . No clinically significant malignant pericardial effusion . No CNS metastasis . No unintended weight loss ( &gt; 5 % body weight ) precede 90 day prior registration initial therapy . No treatment investigational agent within 30 day prior register initial therapy . No prior therapy Ras pathway inhibitor antiangiogenic agent . No active cancer . Females must breastfeed . No active clinically serious infection judge treat investigator ( &gt; CTC v3 , Grade 2 ) include know human immunodeficiency virus ( HIV ) infection chronic Hepatitis B C. No major surgical procedure , open biopsy , significant traumatic injury within 28 day prior registration initial therapy . No anticipation need major surgical procedure course study . No minor surgical procedure fine needle aspiration cone biopsy within 7 day prior registration initial therapy . No history allergic reaction drug utilize vehicle polysorbate 80 + polyethylene glycol ( etoposide ) . No history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior registration initial therapy . No use inhibitors inducer cytochrome p450 system CYP3A4 enzyme medication aprepitant , ketoconazole , itraconazole , quinidine , digoxin , cyclosporine , ritonavir , grapefruit product , St. John 's Wort , rifampin ( rifampicin ) , carbamazepine , phenytoin , dexamethasone , phenobarbital . No evidence history bleed diathesis coagulopathy . No serious nonhealing wound , ulcer , bone fracture . No know suspect allergy sorafenib . No uncontrolled hypertension define systolic blood pressure &gt; 150 mm Hg diastolic pressure &gt; 90 mm Hg , despite optimal medical management . No thrombolic embolic event cerebrovascular accident include transient ischemic attack within 6 month prior registration initial therapy . No pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 week prior registration initial therapy . No hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 week prior registration initial therapy . No condition impair patient 's ability swallow whole pill malabsorption problem .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>